Annelise Vuidepot, PhD profile page

Dr. Annelise Vuidepot joined Immunocore, formerly Avidex, at its founding in 2000. She has played a lead role in pioneering a novel class of T-cell receptor-based therapeutics. Prior to joining Immunocore, Vuidepot was a postdoctoral researcher in the biochemistry department at University College London. She holds a master’s degree in chemistry from the Paris-Sorbonne University and a PhD in Biophysics from Ecole Polytechnique in Saclay, France. Vuidepot currently leads the company’s enterprise technology strategy and the evolution of the ImmTAX platform, driving both scientific innovation and long-term strategic growth. She has been a key contributor to the company's growth from a start-up to a globally recognized biotech leader, with the commercialization of its first approved drug in 2022. Acting as a key integrator between research, development, and manufacturing sciences, she ensures that research translates into impactful therapeutic solutions for patients. Vuidepot also serves as UK site head, representing Immunocore within the UK biotech ecosystem and leading initiatives that foster a collaborative, innovative, and world-class scientific environment. In addition, she is a non-executive director at Advanced Oxford, where she advocates for policies that support sustainable growth.